Medical Technology / Diagnostic Imaging & Therapeutic Equipment
Strategic Profile
The company emphasizes its 'Elevating Health Globally' strategy, focusing on patient twinning, healthcare AI, and precision therapy to address major health challenges including neurodegenerative diseases, cardiovascular conditions, stroke, and cancer. Siemens AG announced its decision to deconsolidate its remaining approximately 67% stake in Siemens Healthineers, handing a 30% stake to its own shareholders to reduce exposure to medical technology and focus on software. Revenue growth of about 5.7% per year is described as slightly below the wider German market forecast, with the bullish view leaning more on efficiency and margin support than on outperformance in sales growth.
Cyborg Score Rationale
The company reported a net profit margin of 9.1% with trailing twelve month revenue at €23.3 billion and net income of roughly €2.1 billion, backed by multi-year earnings growth of 4.9% per year and 6.8% over the last twelve months. However, the company's high level of debt is flagged as a financial risk, and Q1 FY2026 showed a 3% decline in adjusted earnings per share despite 4% revenue growth.
Top Insights
China revenue remains flat with no market recovery expected in 2026; tariff impact of approximately €400 million is expected in 2026
Healthy book-to-bill ratio of 1.14x in FY 2025 reflects intact underlying demand; diversified portfolio across Imaging, Varian, and Advanced Therapeutics provides counterbalance to adverse outcomes
Company confirmed FY2026 outlook projecting 5% to 6% revenue growth and adjusted EPS between €2.20 and €2.40
Preparations for deconsolidation from Siemens AG are advancing well with strong investment-grade rating from Moody's providing financial flexibility
Named Competitors
Philips Healthcare — Medical imaging and diagnostic systems
GE Healthcare — Diagnostic imaging and healthcare IT solutions
Drägerwerk — Medical and safety technology systems
Varian Oncology — Cancer treatment and radiation therapy systems
Recent Developments
(February 2026) Q1 FY2026 revenue grew 4% to €5.4 billion but adjusted EPS declined 3% to €0.49, highlighting gap between operational improvements and bottom-line results
(November 2025) Siemens AG announced plan to deconsolidate 67% stake in Siemens Healthineers by distributing 30% to shareholders
(November 2025) FY2025 closed at upper end of guidance ranges with broad-based revenue and EPS growth except in China; book-to-bill ratio of 1.14x supports demand outlook
Open the full interactive Siemens Healthineers AG report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.